Antithrombin Market size in 2019 is estimated to be $530.65 million, growing at a CAGR of 5.6% during the forecast period 2020-2025. Antithrombin is a type of protein in human blood which plays important role prevention of blood clotting as it acts as a natural blood thinner and extensively used while performing surgical procedures in the patient with low antithrombic levels. Antithrombin is a serpin (serine protease inhibitor) which is similar in structure to most other plasma protease inhibitors. Increasing number of surgical procedures and technological advancement are the major factors driving the growth of the market. Moreover, changing rising geriatric population and increasing incidence of coagulation disorders further enhance the overall market demand for Antithrombic during the forecast period 2020-2025.
Application – Segment Analysis
Based on the Application, Antithrombic Market is segmented into Therapeutics, Research, Diagnostics, and Others. The therapeutics drugs segment is poised to be the fastest-growing segment and is projected to grow at a CAGR of 3.9% during the forecast period 2020-2025. This is mainly owing to increasing prevalence of antithrombic deficiency and growing incidence of bleeding during surgical procedures. Moreover, availability of therapeutic antithrombin preparation with approved indications and increasing research activities are contributing to the growth of this segment.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=15602
Report Price: $ 4500 (Single User License)
Dosage Form – Segment Analysis
Based on the Dosage Form, Antithrombic Market is segmented into Lyophilized, Liquid. In 2019, lyophilized held the largest share in the Antithrombic Market. The lyophilized dosage form has long expiry date and they are widely available. Moreover, it maximize the integrity and easy of processing a liquid is also contributing to the growth of this segment.
Geography – Segment Analysis
North America dominated the Antithrombin Market share accounting for 45% of the market in 2019. This is mainly owing to increasing number of approval for antithrombic, high awareness and developed technology. According to U.S. Department of Health and Human Services, about 1 in 2,000 people are suffering from antithrombin deficiency and around 9000 people is affected from venous thromboembolism every year in the U.S.
However, the Asia-Pacific region is projected to be the fastest-growing during the forecast period 2020-2025. This is owing to improving healthcare infrastructure and increasing research and development activities.
Drivers – Antithrombic Market
Increasing Number of Surgical Procedures
Increasing number of surgical procedures and increasing cases of extracorporeal membrane oxygenation and hereditary antithrombin deficiency are some factors driving the growth of Antithrombic Market. Moreover, increasing number of cases of coagulation disorder and rising prevalence of medical conditions such as sepsis is also set to increase the market growth.
Technological advancement and development of antithrombic and advancements in drug administering technology are some factors driving the growth of the market. Moreover, development of new types of antithrombin products with different indication and increasing number of product approvals further contributing to the growth of Antithrombic Market.
Talk to one of our sales representative about the full report by providing your details in the link below:
Challenges – Antithrombic Market
High price of antithrombic and increasing alternatives of antithrombic are challenging the growth of the market. Moreover, increasing regulations on animal testing have impeded a number of healthcare companies from manufacturing new drugs are further restraining its market growth during the forecast period 2020-2025.
Antithrombic Industry Outlook
Product launches, Merger & Acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Antithrombic Market. Antithrombic top 10 companies are Grifols, Shire Plc., CSL Limited, Kedrion S.p.A., Octapharma AG, Lee Biosolutions, Scripps Laboratories Inc., Kyowa Hakko Kirin Co. Ltd., and Janssen Pharmaceuticals Inc.
On September 2017, Kyowa Hakko Kirin Co. Ltd. Launches new ACOALAN injection 1800 which is specially designed to avoid the infection caused by human blood. The main aim is to provide people new technologies which can help them to get better life and health.
On March 2016, Janssen Pharmaceuticals Inc. has an acquisition with XO1 Limited who develops the anti-thrombin antibody ichorcumab.
In 2019, North America dominates the Antithrombic Market owing to increasing number of approval for antithrombic, high awareness and developed technology.
Increasing number of surgical procedures and technological advancement is driving the market growth of antithrombic.
Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Antithrombic Market report.
High price of antithrombic and increasing alternatives of antithrombic are challenging the growth of the market.
Related Reports :
A. Antiemetic Drugs Market
B. Extracorporeal Membrane Oxygenation Machine Market
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to firstname.lastname@example.org to discuss more about our consulting services.